Remdesivir for the Treatment of Severe COVID-19

Remdesivir for the Treatment of Severe COVID-19

Coronavirus, Therapeutic

1 Hour 30 Minutes

English Site

Online

982 / 1000 Seats

Course Overview

 

Welcome to an exciting international exchange of experiences on "Remdesivir for the Treatment of Severe COVID-19"; the live webinar was held on 28th August 2020. 

In India, Remdesivir has been approved for emergency use in patients hospitalized with severe COVID-19 and has shown promising results. There is a need to more critically understand the utility of this drug, and who better to share experiences than the Clinical Trial Lead Investigator, Dr. Goldmann (Fred Hutchinson Cancer Research Ctr, Seattle, USA) and Dr. Kumarasamy (Infectious Disease Specialist, Chief & Director, VHS Infectious Diseases Medical Centre, India, who also serves on ICMR National Task Force on COVID-19 )


What was discussed:
Module 1: (Start time: 00min:11sec, End time:00min:55 sec): Dr. Ravi Shankar (Head Medical Affairs India & Emerging Markets, Mylan) addressed the speakers and participants.

Module 2 (Start time:01min:27sec, End time:02min:29sec): Mr. Naresh Hasija (Associate Vice President, Public Health, Mylan India) provides a welcome note to the speakers laying the context for the attendees.

Module 3 (Start time: 04min:35sec, End time: 55min:30sec): Dr. Jason D Goldman discusses the state of  Contentious Issues and Evolving Concepts in the Management of Severe COVID-19- Role of Remdesivir.
Module 4 (Start time:56min:14sec, End time: 01hr:41min:20sec):  Dr. N Kumarasamydiscussed about Remdesivir for Managing Severe COVID19, related to the Indian Context.

Module 5 (Question and Answer, Start time:01hr:41min:39sec, End time:01hr:56min:55sec): Dr Sanjay (Medical, Mylan)  moderated the >100 questions asked by attendees for speakers pertaining to Remdesivir, patient real time experiences, drug interactions, cytokine storm and other relevant topics. After the Q&A, a poll was raised and a vote of thanks concluded the webinar.


Trainers


Agenda

Introduction: Dr. Ravi Shankar (Head Medical Affairs india & Emerging Markets, Mylan)
Welcome Note: Mr. Naresh Hasija (Associate Vice President, Public Health, Mylan India)
Speakers:
Dr. Jason D Goldman: Contentious Issues and Evolving Concepts in the Management of Severe COVID-19- Role of Remdesivir 
Dr. N. Kumarasamy Remdesivir for Managing Severe COVID19 – Indian Context
Question and Answer
Conclusion: Dr. Ravi Shankar



Coming session Starts Aug 28, 2020
Ends Nov 29, 2020